DUBLIN – Top-line data from a placebo-controlled phase II trial of Vicore Pharma Holding AB’s angiotensin II type two receptor agonist, C21, provide preliminary evidence that the oral drug may provide benefit to patients with severe COVID-19 disease on top of steroid therapy.

LONDON – The Oxford University team behind the development of Astrazeneca plc’s COVID-19 vaccine have become the first to publish full and complete interim phase III data in a peer-reviewed journal.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Altimmune, Arena, Astrazeneca, Axsome, Bellus, Cardior, Curis, Domain, Harpoon, Larimar, Monopar, Novaliq, Panbela, Sojournix, Vicore, Xenon.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Alx, Arch Oncology, Arcturus, Arcutis, Brickell, Cel-Sci, Cytokinetics, Dare, Eisai, Genetx, Hookipa, Inovio, KPB, Lyra, Magenta, Neurorx, Odonate, Relief, Relmada, Sarepta, Tonix, Ultragenyx, Ysopia.

The independent data monitoring committee overseeing Cortexyme Inc.’s phase II/III trial of atuzaginstat (COR-388), a gingipain inhibitor for patients with Alzheimer’s disease, has recommended the study continue to its one-year endpoint.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Apeiron, Ascletis, Clover, Cortexyme, Precision, Takeda, Sutro.

The phase III study of Zepzelca (lurbinectedin) as combination therapy from Jazz Pharmaceuticals plc and Pharmamar SA was a stumble, but the companies said they found plenty of encouraging data prompting them to continue development.